Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 312

Sort by

Sort Order Select

Journal Articles

Increased Mortality and Bleeding in a Large Cohort of Patients on Heparin Anticoagulation Therapy with Discordant Anti-Factor Xa Activity and Activated Partial Thromboplastin Time (PTT); Implications for Clinical Management

Saurabh Gombar, MD PhD, Derek Boothroyd, PhD, Anandi Krishnan, PhD, Husham Sharifi, MD, Joe Hsu, MD, James Zehnder, MD

Blood (2019) 134 (Supplement_1): 712.

https://doi.org/10.1182/blood-2019-132112

Published: 2019

Journal Articles

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Fakiha Siddiqui, Alfonso J Tafur, MD MS, Debra Hoppensteadt, PhD, Jeanine Walenga, PhD, Walter Jeske, PhD, Emily Bontekoe, Ahmed Kouta, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1158.

https://doi.org/10.1182/blood-2019-127072

Published: 2019

Journal Articles

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Nabil K. Thalji, MD PhD, Prakash A Patel, MD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 3640.

https://doi.org/10.1182/blood-2019-125955

Published: 2019

Journal Articles

Catheter Directed Thrombolytic Therapy for Pediatric Cerebral Sinus Vein Thrombosis

Marcela Torres, MD, Tyler Hamby, PhD, Sarah Philip, MDcal Student, Jo Ann Tilley, DNP, APRN, CPNP

Blood (2019) 134 (Supplement_1): 3666.

https://doi.org/10.1182/blood-2019-132082

Published: 2019

Journal Articles

A Retrospective Review of Hospital-Acquired Venous Thromboembolism at a Large Pediatric Tertiary Care Center

Marissa A. Just, MD, Joanna Robles, MD, Karan R. Kumar, MD MS, Andrew Yazman, BS, MMCi, Jennifer A. Rothman, MD, Kristy S. Pahl, MD

Blood (2019) 134 (Supplement_1): 3471.

https://doi.org/10.1182/blood-2019-129398

Published: 2019

Journal Articles

Risk of Intracerebral Hemorrhage with and without Anticoagulation in Patients with Brain Metastasis: The Cleveland Clinic Experience

Tariq Zuheir Kewan, MD, Shafia Rahman, MBBS, Fahrettin Covut, MD, Ramsha Ahmed, MD, Seba Hasan, Yihong Zhou, MD, Alok A Khorana, MD

Blood (2019) 134 (Supplement_1): 3683.

https://doi.org/10.1182/blood-2019-131758

Published: 2019

Journal Articles

Cerebral Venous Thrombosis Case Series at a Tertiary Care Hospital: Exploring Treatment Safety and Efficacy of Direct Oral Anticoagulants

Mohammed Abdullah Alsheef, MD, Mukhtar Alomar, PharmD, Abdul Rehman Z. Zaidi, MBBS, Ghaydaa Juma Kullab, MD, Mohammed AlHazzaa, MD, Asaad Bafaraj, MD, Abdullah Badahman, MD

Blood (2019) 134 (Supplement_1): 3658.

https://doi.org/10.1182/blood-2019-128406

Published: 2019

Journal Articles

Bovine Heparin Demonstrates the Same Interaction with HIT Antibodies As Porcine Heparin

Jeanine Walenga, PhD, Walter Jeske, PhD, Sabrina Bertini, Giulia Risi, Michelle Sung, BS, Ambar Farooqui, Cassie Bacher, Debra Hoppensteadt, PhD, Omer Iqbal, MD, Bruce Lewis, Mamdouh Bakhos, MD

Blood (2019) 134 (Supplement_1): 2351.

https://doi.org/10.1182/blood-2019-127304

Published: 2019

Journal Articles

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Brandon Tse, Gloria Lim, MDFRCPC,MSc, Michelle Sholzberg, MDBSc,FRCPC,MSc, Katerina Pavenski, MD

Blood (2019) 134 (Supplement_1): 2381.

https://doi.org/10.1182/blood-2019-123081

Published: 2019

Journal Articles

Comparative Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies

Ambar Farooqui, Debra Hoppensteadt, PhD, Omer Iqbal, MD, Cassie Bacher, Jeanine Walenga, PhD, Ahmed Kouta, Walter Jeske, PhD, Bruce Lewis, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 2446.

https://doi.org/10.1182/blood-2019-131825

Published: 2019

Journal Articles

The Incidence of Heparin Induced Thrombocytopenia before and after the Implementation of the Venous Thromboembolism Thromboprophylaxis Protocols within Eastern Health

Kristina Roche, Brian Harnett, MD, Leona Browne, Stephanie Young, PharmD, Rufaro S. Chitsike, MD

Blood (2019) 134 (Supplement_1): 2447.

https://doi.org/10.1182/blood-2019-129340

Published: 2019

Journal Articles

To Assess the Appropriateness of the Venous Thromboembolism (VTE) Prophylaxis Agent Used Based on the VTE Risk Stratification in Hospitalised Acutely Ill Medical Patients

Maitreyee Rai, MBBS, Jian Liang Tan, MD, Meghana Parsi, MD, Malvika Duphare, DO, Mylene S. Go, MD

Blood (2019) 134 (Supplement_1): 2444.

https://doi.org/10.1182/blood-2019-122402

Published: 2019

Journal Articles

USP Potency Adjusted Bovine Mucosal Heparins (BMH) Are Comparable to Porcine Mucosal Heparin (PMH) at Equivalent Levels

Ahmed Kouta, Walter Jeske, PhD, Rick Duff, Debra Hoppensteadt, PhD, Omer Iqbal, MD, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 165.

https://doi.org/10.1182/blood-2019-131943

Published: 2019

Journal Articles

VTE Incidence in RRMM Patients Treated with NOVEL Agents: A Monocentric Real Life Experience

Gaetano Giuffrida, MD, Concetta Conticello, MD, Valeria Calafiore, Enrica Antonia Martino, MD, Silvia Giamporcaro, MD, Alessandra Romano, MD PhD, Francesco Di Raimondo, MD

Blood (2019) 134 (Supplement_1): 4972.

https://doi.org/10.1182/blood-2019-131015

Published: 2019

Journal Articles

The Real World Experience Regarding the Safety of Rivaroxaban and Apixaban in Venous Thromboembolism Patients with High Bleeding Risk

Haoxu Ouyang, MD PhD, Ratesh Khillan, Nyein Htway Yu, MBBS, MD, Mohan Preet, MD

Blood (2019) 134 (Supplement_1): 4927.

https://doi.org/10.1182/blood-2019-132283

Published: 2019

Journal Articles

Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism

Rachel P Rosovsky, MDMPH, Islam Y Elgendy, MD, Suzanne C Cannegieter, MD PhD, Menno V Huisman, MD PhD, David Jimenez, MD PhD, Jorge del Toro, MD, Vladimir Rosa, MD PhD, Carmen Fernández-Capitán, MD PhD, Alessandra Bura-Riviere, MD PhD, Manuel Monreal, MD PhD

Blood (2019) 134 (Supplement_1): 2429.

https://doi.org/10.1182/blood-2019-131090

Published: 2019

Journal Articles

Monitoring Unfractionated Heparin Treatments. Stability of Plasma Anti-Xa Activity up to 4 Hours in Citrated Tubes

Anny Appert-Flory, MD, Florence Fischer, MD, Didier Jambou, MD, Sylvain Buvat, Marie-Helene Mahagne, MD, Pierre Toulon, MD

Blood (2019) 134 (Supplement_1): 3403.

https://doi.org/10.1182/blood-2019-130533

Published: 2019

Journal Articles

Potential Overuse of Primary Thromboprophylaxis in Medical Inpatients at Low Risk of Venous Thromboembolism

Mia Djulbegovic, MD, Kevin Chen, MD, Soundari Sureshanand, MCA, Sarwat Chaudhry, MD

Blood (2019) 134 (Supplement_1): 3385.

https://doi.org/10.1182/blood-2019-131827

Published: 2019

Journal Articles

Is There an Alternative to Serotonin Release Assay for the Diagnosis of Heparin Induced Thrombocytopenia (HIT)? Evaluation of 5 Other Functional Methods Using 5B9 a Monoclonal IgG That Mimics HIT Human Antibodies

Eve-Anne Guéry, PharmD, Caroline Vayne, PharmD, Cloé Derray, Joévin Besombes, Wayne Corentin Lambert, Jérôme Rollin, PhD, Yves Gruel, MD PhD, Claire Pouplard, PharmD, PhD

Blood (2018) 132 (Supplement 1): 3742.

https://doi.org/10.1182/blood-2018-99-115011

Published: 2018

Journal Articles

JNJ-64179375 Inhibits Exosite I-Mediated Thrombin Activity While Preserving Exosite II and Active Site Function in Vitro

Matthew Bunce, PhD, Madhu Chintala, PhD, Sriram Krishnaswamy, PhD, Harlan N Bradford, BA

Blood (2018) 132 (Supplement 1): 24.

https://doi.org/10.1182/blood-2018-99-116291

Published: 2018

NARROW

Increased Mortality and Bleeding in a Large Cohort of Patients on Heparin Anticoagulation Therapy with Discordant Anti-Factor Xa Activity and Activated Partial Thromboplastin Time (PTT); Implications for Clinical Management

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Catheter Directed Thrombolytic Therapy for Pediatric Cerebral Sinus Vein Thrombosis

A Retrospective Review of Hospital-Acquired Venous Thromboembolism at a Large Pediatric Tertiary Care Center

Risk of Intracerebral Hemorrhage with and without Anticoagulation in Patients with Brain Metastasis: The Cleveland Clinic Experience

Cerebral Venous Thrombosis Case Series at a Tertiary Care Hospital: Exploring Treatment Safety and Efficacy of Direct Oral Anticoagulants

Bovine Heparin Demonstrates the Same Interaction with HIT Antibodies As Porcine Heparin

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Comparative Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies

The Incidence of Heparin Induced Thrombocytopenia before and after the Implementation of the Venous Thromboembolism Thromboprophylaxis Protocols within Eastern Health

To Assess the Appropriateness of the Venous Thromboembolism (VTE) Prophylaxis Agent Used Based on the VTE Risk Stratification in Hospitalised Acutely Ill Medical Patients

USP Potency Adjusted Bovine Mucosal Heparins (BMH) Are Comparable to Porcine Mucosal Heparin (PMH) at Equivalent Levels

VTE Incidence in RRMM Patients Treated with NOVEL Agents: A Monocentric Real Life Experience

The Real World Experience Regarding the Safety of Rivaroxaban and Apixaban in Venous Thromboembolism Patients with High Bleeding Risk

Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism

Monitoring Unfractionated Heparin Treatments. Stability of Plasma Anti-Xa Activity up to 4 Hours in Citrated Tubes

Potential Overuse of Primary Thromboprophylaxis in Medical Inpatients at Low Risk of Venous Thromboembolism

Is There an Alternative to Serotonin Release Assay for the Diagnosis of Heparin Induced Thrombocytopenia (HIT)? Evaluation of 5 Other Functional Methods Using 5B9 a Monoclonal IgG That Mimics HIT Human Antibodies

JNJ-64179375 Inhibits Exosite I-Mediated Thrombin Activity While Preserving Exosite II and Active Site Function in Vitro

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only